Neuroblastoma genetic study for children and young adults
Part of Cancer clinical trials.
This study looks at the genetic and biological details of neuroblastoma tumors to better understand the disease. It may help find better treatments in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child are 0 to 31 years old.
- You have a diagnosis of neuroblastoma at an AIEOP center (a participating Italian hospital).
- You or your legal guardian sign a consent form to take part.
- You have a life expectancy of more than 3 months.
- Fresh tumor tissue, bone marrow, and blood samples are available for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how high-risk neuroblastoma grows and behaves by collecting samples from your child and checking disease markers. It may help researchers understand what biology is driving the cancer and guide future treatments.
This study creates an international registry linked to a virtual biobank, so researchers can collect and share information and biological samples for patients with specific peripheral neuroblastic tumors. It may help future research and care planning by improving what scientists know about these conditions.
This trial uses special lab models (“immune organoids”) to study certain cancers in children and young people. It may help researchers learn what those cancers do and improve future treatment ideas.
This study collects blood samples from neuroblastoma patients to test for tiny pieces of tumor DNA that can show how well treatment is working. By tracking these markers over time, doctors hope to better predict how patients will respond and improve care.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.